Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to Keytruda (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination therapies and achieve cancer control with this approach to treatment.
We lost Jeff Weber, an amazing medical oncologist, an impactful clinical scientist, a leading immunotherapist, and one of the prominent global experts in melanoma.
